Your browser doesn't support javascript.
loading
Whole-genome sequencing of a sporadic primary immunodeficiency cohort.
Thaventhiran, James E D; Lango Allen, Hana; Burren, Oliver S; Rae, William; Greene, Daniel; Staples, Emily; Zhang, Zinan; Farmery, James H R; Simeoni, Ilenia; Rivers, Elizabeth; Maimaris, Jesmeen; Penkett, Christopher J; Stephens, Jonathan; Deevi, Sri V V; Sanchis-Juan, Alba; Gleadall, Nicholas S; Thomas, Moira J; Sargur, Ravishankar B; Gordins, Pavels; Baxendale, Helen E; Brown, Matthew; Tuijnenburg, Paul; Worth, Austen; Hanson, Steven; Linger, Rachel J; Buckland, Matthew S; Rayner-Matthews, Paula J; Gilmour, Kimberly C; Samarghitean, Crina; Seneviratne, Suranjith L; Sansom, David M; Lynch, Andy G; Megy, Karyn; Ellinghaus, Eva; Ellinghaus, David; Jorgensen, Silje F; Karlsen, Tom H; Stirrups, Kathleen E; Cutler, Antony J; Kumararatne, Dinakantha S; Chandra, Anita; Edgar, J David M; Herwadkar, Archana; Cooper, Nichola; Grigoriadou, Sofia; Huissoon, Aarnoud P; Goddard, Sarah; Jolles, Stephen; Schuetz, Catharina; Boschann, Felix.
Afiliación
  • Thaventhiran JED; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK. jedt2@cam.ac.uk.
  • Lango Allen H; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK. jedt2@cam.ac.uk.
  • Burren OS; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK. jedt2@cam.ac.uk.
  • Rae W; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Greene D; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Staples E; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Zhang Z; Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Farmery JHR; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
  • Simeoni I; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Rivers E; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
  • Maimaris J; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Penkett CJ; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Stephens J; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Deevi SVV; Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge Biomedical Campus, Cambridge, UK.
  • Sanchis-Juan A; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Gleadall NS; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
  • Thomas MJ; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Sargur RB; Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Gordins P; Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge Biomedical Campus, Cambridge, UK.
  • Baxendale HE; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
  • Brown M; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Tuijnenburg P; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Worth A; UCL Great Ormond Street Institute of Child Health, London, UK.
  • Hanson S; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Linger RJ; UCL Great Ormond Street Institute of Child Health, London, UK.
  • Buckland MS; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Rayner-Matthews PJ; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Gilmour KC; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Samarghitean C; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Seneviratne SL; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Sansom DM; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Lynch AG; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Megy K; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Ellinghaus E; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Ellinghaus D; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Jorgensen SF; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Karlsen TH; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Stirrups KE; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Cutler AJ; Department of Immunology, Queen Elizabeth University Hospital, Glasgow, UK.
  • Kumararatne DS; Gartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
  • Chandra A; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Edgar JDM; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Herwadkar A; East Yorkshire Regional Adult Immunology and Allergy Unit, Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.
  • Cooper N; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.
  • Grigoriadou S; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Huissoon AP; Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
  • Goddard S; Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.
  • Jolles S; NIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Schuetz C; Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam, The Netherlands.
  • Boschann F; Department of Experimental Immunology, Amsterdam University Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.
Nature ; 583(7814): 90-95, 2020 07.
Article en En | MEDLINE | ID: mdl-32499645
ABSTRACT
Primary immunodeficiency (PID) is characterized by recurrent and often life-threatening infections, autoimmunity and cancer, and it poses major diagnostic and therapeutic challenges. Although the most severe forms of PID are identified in early childhood, most patients present in adulthood, typically with no apparent family history and a variable clinical phenotype of widespread immune dysregulation about 25% of patients have autoimmune disease, allergy is prevalent and up to 10% develop lymphoid malignancies1-3. Consequently, in sporadic (or non-familial) PID genetic diagnosis is difficult and the role of genetics is not well defined. Here we address these challenges by performing whole-genome sequencing in a large PID cohort of 1,318 participants. An analysis of the coding regions of the genome in 886 index cases of PID found that disease-causing mutations in known genes that are implicated in monogenic PID occurred in 10.3% of these patients, and a Bayesian approach (BeviMed4) identified multiple new candidate PID-associated genes, including IVNS1ABP. We also examined the noncoding genome, and found deletions in regulatory regions that contribute to disease causation. In addition, we used a genome-wide association study to identify loci that are associated with PID, and found evidence for the colocalization of-and interplay between-novel high-penetrance monogenic variants and common variants (at the PTPN2 and SOCS1 loci). This begins to explain the contribution of common variants to the variable penetrance and phenotypic complexity that are observed in PID. Thus, using a cohort-based whole-genome-sequencing approach in the diagnosis of PID can increase diagnostic yield and further our understanding of the key pathways that influence immune responsiveness in humans.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Secuenciación Completa del Genoma / Enfermedades de Inmunodeficiencia Primaria Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Nature Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Secuenciación Completa del Genoma / Enfermedades de Inmunodeficiencia Primaria Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Nature Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido